Lonza Group Ltd, a market leading custom manufacturer of Biopharmaceuticals, announces that it has entered into an agreement with Micromet, Inc for the process development and manufacture of Micromet’s blinatumomab (MT103). Micromet is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases.
Under the terms of the agreement, Lonza will manufacture blinatumomab for clinical trials. In addition, Lonza will develop the commercial scale process and will supply blinatumomab for the market if so requested by Micromet.
Blinatumomab (MT103) is a BiTE antibody for the treatment of various haematologic cancers. Blinatomumab has achieved the primary endpoint in a phase-2 clinical trial for the treatment of patients with acute lymphoblastic leukaemia (ALL), and has shown significant clinical activity in an ongoing phase-1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL).
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries.
Micromet is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases.